JP2020117553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020117553A5 JP2020117553A5 JP2020086708A JP2020086708A JP2020117553A5 JP 2020117553 A5 JP2020117553 A5 JP 2020117553A5 JP 2020086708 A JP2020086708 A JP 2020086708A JP 2020086708 A JP2020086708 A JP 2020086708A JP 2020117553 A5 JP2020117553 A5 JP 2020117553A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cobicistat
- drug
- vincristine
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 67
- 206010028980 Neoplasm Diseases 0.000 claims 47
- 201000011510 cancer Diseases 0.000 claims 46
- 229940041181 antineoplastic drug Drugs 0.000 claims 42
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 claims 37
- 229960002402 cobicistat Drugs 0.000 claims 37
- 229960004528 vincristine Drugs 0.000 claims 24
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical group C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 24
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 23
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 21
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 21
- 206010006187 Breast cancer Diseases 0.000 claims 18
- 208000026310 Breast neoplasm Diseases 0.000 claims 18
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 18
- 208000000453 Skin Neoplasms Diseases 0.000 claims 18
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 18
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 18
- 201000010536 head and neck cancer Diseases 0.000 claims 18
- 208000014829 head and neck neoplasm Diseases 0.000 claims 18
- 201000005202 lung cancer Diseases 0.000 claims 18
- 208000020816 lung neoplasm Diseases 0.000 claims 18
- 201000000849 skin cancer Diseases 0.000 claims 18
- 201000002510 thyroid cancer Diseases 0.000 claims 18
- 206010046766 uterine cancer Diseases 0.000 claims 18
- 206010008342 Cervix carcinoma Diseases 0.000 claims 17
- 206010033128 Ovarian cancer Diseases 0.000 claims 17
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 17
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 17
- 201000010881 cervical cancer Diseases 0.000 claims 17
- 201000003733 ovarian melanoma Diseases 0.000 claims 17
- 201000008017 ovarian lymphoma Diseases 0.000 claims 16
- 206010009944 Colon cancer Diseases 0.000 claims 15
- 208000029742 colonic neoplasm Diseases 0.000 claims 15
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 14
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 14
- 201000002528 pancreatic cancer Diseases 0.000 claims 14
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 14
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 12
- 230000001965 increasing effect Effects 0.000 claims 12
- 229960003048 vinblastine Drugs 0.000 claims 12
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 12
- 230000004060 metabolic process Effects 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 3
- 210000000496 pancreas Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371105P | 2016-08-04 | 2016-08-04 | |
| US62/371,105 | 2016-08-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505383A Division JP6764017B2 (ja) | 2016-08-04 | 2017-08-01 | がんの処置での使用のためのコビシスタット |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170294A Division JP2021001235A (ja) | 2016-08-04 | 2020-10-08 | がんの処置での使用のためのコビシスタット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020117553A JP2020117553A (ja) | 2020-08-06 |
| JP2020117553A5 true JP2020117553A5 (enExample) | 2020-12-24 |
Family
ID=59579948
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505383A Active JP6764017B2 (ja) | 2016-08-04 | 2017-08-01 | がんの処置での使用のためのコビシスタット |
| JP2020086708A Withdrawn JP2020117553A (ja) | 2016-08-04 | 2020-05-18 | がんの処置での使用のためのコビシスタット |
| JP2020170294A Withdrawn JP2021001235A (ja) | 2016-08-04 | 2020-10-08 | がんの処置での使用のためのコビシスタット |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505383A Active JP6764017B2 (ja) | 2016-08-04 | 2017-08-01 | がんの処置での使用のためのコビシスタット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170294A Withdrawn JP2021001235A (ja) | 2016-08-04 | 2020-10-08 | がんの処置での使用のためのコビシスタット |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180036289A1 (enExample) |
| EP (1) | EP3493797A1 (enExample) |
| JP (3) | JP6764017B2 (enExample) |
| AU (2) | AU2017305303B2 (enExample) |
| CA (1) | CA3032813A1 (enExample) |
| MA (1) | MA45848A (enExample) |
| TW (2) | TW202123943A (enExample) |
| WO (1) | WO2018026835A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TWI705813B (zh) * | 2019-05-24 | 2020-10-01 | 國立交通大學 | 含有ganetespib的粒子與含有該粒子的藥學組成物及其在抗癌治療上的用途 |
| CN119632992A (zh) * | 2019-06-21 | 2025-03-18 | 帕特恩电脑公司 | 用于治疗癌症的治疗性组合物和方法 |
| JP7728264B2 (ja) * | 2020-01-10 | 2025-08-22 | 武田薬品工業株式会社 | シトクロムｐ４５０の阻害剤を用いて３－（（メチルスルホニル）アミノ）－２－（（（４－フェニルシクロヘキシル）オキシ）メチル）ピペリジン－１－カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法 |
| CN115643797A (zh) * | 2020-04-30 | 2023-01-24 | 天境生物科技(上海)有限公司 | 包含抗cd47抗体的药物组合物 |
| WO2021231611A1 (en) * | 2020-05-12 | 2021-11-18 | Splash Pharmaceuticals, Inc. | Methods for treating cancer using spl-108 polypeptide based on tp53 mutational status |
| CN114762691A (zh) * | 2021-01-12 | 2022-07-19 | 中国科学院上海药物研究所 | 双嘧达莫在抗肿瘤中的应用 |
| CN113577304B (zh) * | 2021-07-26 | 2023-12-26 | 深圳市泰尔康生物医药科技有限公司 | 一种针对乳腺癌her2靶点的多肽偶联药物的开发及应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
| FR2828206B1 (fr) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
| PL1761540T3 (pl) | 2004-05-13 | 2017-06-30 | Icos Corporation | Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta |
| US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| PT2049506E (pt) * | 2006-07-07 | 2015-10-09 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
| BRPI0807581A2 (pt) * | 2007-02-23 | 2014-07-01 | Gilead Science, Inc. | Moduladores de propriedades farmacocinéticas de produtos terapêuticos |
| ES2402334T3 (es) | 2007-08-02 | 2013-04-30 | Gilead Biologics, Inc | Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis |
| US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| BR112012019693A2 (pt) | 2010-02-04 | 2017-06-20 | Gilead Biologics Inc | anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles. |
| KR101827048B1 (ko) | 2010-08-27 | 2018-02-07 | 길리아드 바이오로직스, 인크. | 매트릭스 메탈로프로테이나제 ９에 대한 항체 |
| JP6101205B2 (ja) | 2011-08-23 | 2017-03-22 | 中外製薬株式会社 | 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体 |
| GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
| CN104024257A (zh) | 2011-10-04 | 2014-09-03 | 吉利德卡利斯托加有限责任公司 | Pi3k的新的喹喔啉抑制剂 |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
| WO2014047624A1 (en) | 2012-09-24 | 2014-03-27 | Gilead Sciences, Inc. | Anti-ddr1 antibodies |
| EP2941426B1 (en) | 2012-12-21 | 2018-06-13 | Gilead Calistoga LLC | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| EP2935246B1 (en) | 2012-12-21 | 2018-07-25 | Gilead Calistoga LLC | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
| WO2014159745A1 (en) * | 2013-03-14 | 2014-10-02 | Pharmacyclics, Inc. | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors |
| TWI644909B (zh) | 2013-06-14 | 2018-12-21 | 基利科學股份有限公司 | 磷脂酸肌醇３－激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| WO2016138542A1 (en) * | 2015-02-28 | 2016-09-01 | Cyprus Therapeutics, Inc. | Methods for inhibiting tumors and drug resistance |
| CN114177180A (zh) * | 2015-08-27 | 2022-03-15 | 北京美倍他药物研究有限公司 | 依鲁替尼的药物组合物 |
-
2017
- 2017-08-01 EP EP17751204.3A patent/EP3493797A1/en not_active Withdrawn
- 2017-08-01 CA CA3032813A patent/CA3032813A1/en not_active Abandoned
- 2017-08-01 MA MA045848A patent/MA45848A/fr unknown
- 2017-08-01 WO PCT/US2017/044932 patent/WO2018026835A1/en not_active Ceased
- 2017-08-01 JP JP2019505383A patent/JP6764017B2/ja active Active
- 2017-08-01 US US15/666,417 patent/US20180036289A1/en not_active Abandoned
- 2017-08-01 AU AU2017305303A patent/AU2017305303B2/en active Active
- 2017-08-04 TW TW110103932A patent/TW202123943A/zh unknown
- 2017-08-04 TW TW106126377A patent/TWI718327B/zh not_active IP Right Cessation
-
2020
- 2020-05-18 JP JP2020086708A patent/JP2020117553A/ja not_active Withdrawn
- 2020-07-28 AU AU2020210188A patent/AU2020210188A1/en not_active Abandoned
- 2020-10-08 JP JP2020170294A patent/JP2021001235A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020117553A5 (enExample) | ||
| Ferris et al. | Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression | |
| ES2653615T3 (es) | Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos | |
| Yeung et al. | Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model | |
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| JP2018508516A5 (enExample) | ||
| Budde et al. | A phase I study of pulse high‐dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma | |
| JP2014511383A5 (enExample) | ||
| Tian et al. | Preclinical evaluation of promitil, a radiation-responsive liposomal formulation of mitomycin c prodrug, in chemoradiotherapy | |
| JP2019524888A5 (enExample) | ||
| Mainetti et al. | Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2015510945A5 (enExample) | ||
| SA94140746B1 (ar) | مركب علاجي من /tamoxifen cisplatin للسرطانات في الانسان | |
| Tseng et al. | Magnolol’s Therapeutic Efficacy and Immunomodulatory Effects in Oral Squamous Cell Carcinoma | |
| Aggarwal et al. | Aripiprazole lauroxil long-acting injectable: the latest addition to second-generation long-acting agents | |
| Brunsvig et al. | Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: A Phase I/II study with 5 years’ follow-up | |
| CN102319260A (zh) | 顺铂联合伊曲康唑异构体在制备治疗肺癌药物中的应用 | |
| Arora et al. | Feasibility of preirradiation temozolomide in cases of high-grade gliomas: Our experience and review of literature | |
| Shultes | Loncastuximab Tesirine-lpyl (Zynlonta®) | |
| Basu et al. | Is interferon-α and retinoic acid combination along with radiation superior to chemo-radiation in the treatment of advanced carcinoma of cervix? | |
| Berkson et al. | A review of the integrative treatment approach using the intravenous alpha-lipoic acid/low dose naltrexone (ALA/N) protocol for cancer and a description of the long-term survival of a woman with hepatocellular carcinoma | |
| Teng et al. | Nimotuzumab and irinotecan synergistically induce ROS‐mediated apoptosis by endoplasmic reticulum stress and mitochondrial‐mediated pathway in cervical cancer |